Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effect of Tadalafil in Chronic Obstructive Lung Disease Patients Suffering From Secondary Pulmonary Hypertension

This study has been withdrawn prior to enrollment.
(due to lack of finance)
Sponsor:
Information provided by:
Herlev Hospital
ClinicalTrials.gov Identifier:
NCT00506701
First received: July 23, 2007
Last updated: March 17, 2015
Last verified: July 2007

July 23, 2007
March 17, 2015
February 2008
February 2010   (Final data collection date for primary outcome measure)
Change in 6 min. walking test [ Time Frame: 6 months ]
Same as current
Complete list of historical versions of study NCT00506701 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Effect of Tadalafil in Chronic Obstructive Lung Disease Patients Suffering From Secondary Pulmonary Hypertension
Pilot Study to Investigate the Effect of Tadalafil on Secondary Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease
Tadalafil may lower the pulmonary artery pressure in patients with Chronic Obstructive Lung Disease and secondary pulmonary hypertension and thereby improve patients quality of life.
Twenty outpatients with Chronic Obstructive Lung Disease (COPD) and secondary pulmonary hypertension are treated in a cross-over design with Tadalafil or placebo for 4 weeks. Primary effect parameter is 6 min. walking test.
Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Chronic Obstructive Lung Disease
Drug: Tadalafil
40 mg tablet
Other Name: PDE5 inhibitor
Experimental: Tadalafil treatment 40 mg
Intervention: Drug: Tadalafil
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
February 2010
February 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Clinical diagnosis of Chronic obstructive lung disease

Exclusion Criteria

  • Patients with asthma
Sexes Eligible for Study: All
45 Years to 85 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
 
NCT00506701
25
Yes
Not Provided
Not Provided
Not Provided
Lars C. Laursen, Herlev Hospital
Herlev Hospital
Not Provided
Principal Investigator: Lars C Laursen, MD University of Copenhagen
Herlev Hospital
July 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP